Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
4.790
+0.050 (1.05%)
Mar 6, 2026, 4:00 PM EST - Market closed
Coya Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Revenue | 3.99 | 3.55 | 6 | - | - | - |
| Revenue Growth (YoY) | -58.26% | -40.79% | - | - | - | - |
| Cost of Revenue | 13.73 | 11.87 | 5.5 | 4.41 | - | - |
| Gross Profit | -9.74 | -8.31 | 0.5 | -4.41 | - | - |
| Selling, General & Admin | 10.32 | 8.89 | 7.83 | 4.85 | 2.31 | 0.67 |
| Research & Development | - | - | - | - | 2.54 | 0.04 |
| Operating Expenses | 10.34 | 8.91 | 7.86 | 4.87 | 4.87 | 0.7 |
| Operating Income | -20.09 | -17.22 | -7.36 | -9.29 | -4.87 | -0.7 |
| Interest Expense | - | - | - | - | - | -0.06 |
| Interest & Investment Income | 1.45 | 1.65 | 0.64 | - | - | - |
| Other Non Operating Income (Expenses) | - | - | - | -2.43 | -0.02 | 0 |
| EBT Excluding Unusual Items | -18.64 | -15.58 | -6.72 | -11.72 | -4.89 | -0.76 |
| Pretax Income | -19.15 | -15.6 | -7.26 | -12.24 | -4.89 | -1.1 |
| Income Tax Expense | -0.72 | -0.72 | 0.72 | - | - | - |
| Net Income | -18.43 | -14.88 | -7.99 | -12.24 | -4.89 | -1.1 |
| Net Income to Common | -18.43 | -14.88 | -7.99 | -12.24 | -4.89 | -1.1 |
| Shares Outstanding (Basic) | 17 | 15 | 10 | 3 | 3 | 2 |
| Shares Outstanding (Diluted) | 17 | 15 | 10 | 3 | 3 | 2 |
| Shares Change (YoY) | 19.60% | 49.93% | 292.40% | 0.01% | 40.88% | - |
| EPS (Basic) | -1.11 | -0.98 | -0.79 | -4.73 | -1.89 | -0.60 |
| EPS (Diluted) | -1.11 | -0.98 | -0.79 | -4.73 | -1.89 | -0.60 |
| Free Cash Flow | -12.14 | -10.29 | -11.19 | -7.24 | -4.04 | -0.59 |
| Free Cash Flow Per Share | -0.73 | -0.68 | -1.10 | -2.79 | -1.56 | -0.32 |
| Gross Margin | -244.35% | -233.86% | 8.34% | - | - | - |
| Operating Margin | -503.76% | -484.65% | -122.62% | - | - | - |
| Profit Margin | -462.25% | -418.70% | -133.08% | - | - | - |
| Free Cash Flow Margin | -304.48% | -289.50% | -186.41% | - | - | - |
| EBITDA | -20.06 | -17.2 | -7.33 | -9.26 | -4.85 | - |
| EBITDA Margin | - | - | -122.17% | - | - | - |
| D&A For EBITDA | 0.03 | 0.03 | 0.03 | 0.03 | 0.02 | - |
| EBIT | -20.09 | -17.22 | -7.36 | -9.29 | -4.87 | -0.7 |
| EBIT Margin | - | - | -122.62% | - | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.